Trial Profile

A Phase 2 Photosensitive Epilepsy Proof of concept study of LPCN 2101

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LPCN 2101 (Primary)
Indications Epilepsy
Focus Proof of concept; Therapeutic Use
Sponsors Lipocine

Most Recent Events

11 Jul 2022 According to a Lipocine media release, the U.S. Food and Drug Administration has accepted the company's Investigational New Drug Application for LPCN 2101.
10 Jun 2022 New trial record
06 Jun 2022 According to a Lipocine media release, Pending U.S. FDA clearance of its IND, Lipocine plans to conduct a proof-of-concept study in the second half of 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com